Table 3 |
||||
|
Serial BNP measurements by edema classification |
||||
|
Period |
Direction of BNP change |
n (ΔBNP, pg/ml) |
P |
|
|
|
||||
|
ALI/ARDS |
CHF |
|||
|
|
||||
|
Days 1 to 2 |
Increase |
17 (254 ± 302) |
5 (228 ± 287) |
|
|
Decrease |
9 (-246 ± 178) |
8 (-252 ± 208) |
0.17b |
|
|
Alla |
26 (73 ± 339) |
17 (-52 ± 290) |
0.21c |
|
|
Days 2 to 3 |
Increase |
9 (143 ± 200) |
5 (396 ± 132) |
|
|
Decrease |
11 (-191 ± 187) |
7 (-160 ± 142) |
1.0b |
|
|
Alla |
24 (-34 ± 231) |
15 (57 ± 281) |
0.28c |
|
|
|
||||
|
BNP, B-type natriuretic peptide; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure. The table shows an analysis of changes in BNP levels in direction (increase or decrease) and magnitude (ΔBNP) from day 1 to day 2 and from day 2 to day 3, classified by edema type. Where errors are shown, results are means ± SD. aValues for some patients remained above the upper limit of the assay (1,300 pg/ml) and were consider unchanged. bχ2 comparing the proportion of subjects with an increase in BNP by edema type; ct test of magnitude of BNP change by edema type. |
||||
|
Levitt et al. Critical Care 2008 12:R3 doi:10.1186/cc6764 |
||||
